OvaScience Reports Fourth Quarter and Year-End 2017 Financial Results
– Initial Data from First 20 Patients in Phase 1 Clinical Trial of OvaPrime Indicates Safety and Tolerability; Conducting Additional Preclinical Studies to Optimize Proposed Phase 1b/2a Clinical Trial –
– Appointed James Lillie, Ph.D. as Chief Scientific Officer to Lead Advancement of OvaTure Program –
– Conference Call Today at
“We made a concerted effort over the past six months to hone our
strategic focus on research and development, and are positioned to make
meaningful progress in our OvaPrime and OvaTure programs in 2018,” said
Dr. Kroeger added, “Additionally, Dr.
Recent Business Highlights:
OvaPrimeSM Treatment: OvaPrime is a potential fertility treatment that could help restore a woman’s egg production. With OvaPrime, a woman’s own egg precursor (EggPCSM) cells are isolated from a niche within her ovary where they are quiescent and repositioned such that they receive the appropriate signals to mature in vivo into healthy, fertilizable eggs.
January 2018, OvaSciencereported initial safety data from its single-center, prospective, blinded and placebo-controlled Phase 1 clinical trial of OvaPrime in women with either primary ovarian insufficiency (POI) or poor ovarian response (POR). Among the first 20 patients evaluable for safety six-months post-EggPC cell reintroduction, there were no treatment related serious adverse events and no adverse events (AEs) related to the EggPC cells. There were seven mild AEs, four of which were deemed unrelated to OvaPrime and three of which were related to the standard laparoscopic procedure. No patients discontinued treatment because of an AE. The mean duration of follow-up among these 20 patients was nine months. OvaScienceclosed enrollment in this trial at 81 patients, for a modified intent-to-treat (ITT) population of 58. OvaScienceexpects to announce six-month safety data for all patients by year-end 2018 and to read out initial secondary endpoints for all patients by the end of the third quarter of 2019. Based on preliminary blinded data, OvaSciencedoes not expect the study to result in strong signals on secondary endpoints, which may be due to a sub-optimal EggPC cell dose.
OvaSciencehas since improved its cell processing techniques, resulting in a substantial increase in EggPC cell yield. The Company is conducting preclinical animal studies designed to provide additional data regarding the characteristics of EggPC cells and to evaluate the increased cell yield and purity derived from its improved cell processing techniques. OvaScienceexpects to utilize the findings from these studies to optimize the final design of its proposed multi-center, prospective, controlled, Phase 1b/2a clinical trial of OvaPrime and plans to provide an update on its development plan and begin enrollment in the second half of 2018. As appropriate, OvaSciencealso expects to apply the improvements to its cell processing techniques to ongoing efforts with OvaTure and AUGMENT.
OvaTureSM Treatment: OvaTure is a potential fertility treatment that eliminates the need for hormone stimulation. With OvaTure, a woman’s own EggPC cells are isolated from her ovary and matured in vitro into healthy, fertilizable eggs.
OvaSciencecontinues to progress the preclinical development of OvaTure. The Company is focused on optimizing subculture techniques for the maturation of human and bovine EggPC cells and working with its academic partners to secure authorization to fertilize human EggPC cell-derived eggs outside of the United States.
February 2018, OvaScienceprovided Intrexonwith written termination of the companies’ Exclusive Channel Collaboration Agreement. This decision was based on a belief that OvaSciencecan most effectively develop OvaTure by leveraging internal capabilities along with specialized contract research organizations and select academic institutions that have complementary capabilities. OvaSciencedoes not expect the termination of this collaboration to adversely impact or slow OvaTure development.
AUGMENTSM Treatment: AUGMENT is a
fertility treatment designed to improve fertilization and pregnancy
rates. With AUGMENT, mitochondria from a woman’s own EggPC cells are
isolated and injected into the egg during in vitro fertilization
(IVF). AUGMENT is currently offered to patients through an exclusive
January 2018, OvaScienceannounced the appointment of James Lillie, Ph.D., as Chief Scientific Officer. Dr. Lillie brings extensive cellular biology and biochemistry experience to OvaScienceand is responsible for leading the Company’s preclinical research and development efforts, including the continued advancement of OvaTure.
January 2018, OvaScienceimplemented a corporate restructuring to streamline its operations, reduce its cost structure and extend its cash position beyond a readout of the proposed Phase 1b/2a clinical trial of OvaPrime. In conjunction with this restructuring, OvaSciencereduced its workforce by approximately 50 percent.
Fourth Quarter and Full Year 2017 Financial Results:
Research and development expenses for the quarter ended
December 31, 2017, excluding restructuring costs, were $3.6 million, compared to $4.7 millionfor the same period in 2016. This $1.1 milliondecrease was primarily driven by decreased headcount and employee related costs. Research and development expenses for the full year ended December 31, 2017, excluding restructuring costs, were $18.3 million, compared to $21.6 millionfor the same period in 2016. This year-over-year $3.3 milliondecrease was primarily driven by decreased headcount, employee related costs, including stock based compensation expense, and certain travel and lab supplies. These quarterly and annual decreases resulted from the implementation of OvaScience’s refined corporate strategy in fiscal 2017.
Selling, general and administrative expenses for the quarter ended
December 31, 2017, excluding restructuring costs, were $4.8 million, compared to $10.9 millionfor the same period in 2016. This $6.1 milliondecrease was primarily driven by decreased headcount and employee related costs, reduced consulting and marketing, and reduced travel, facilities and other expenses. Selling, general and administrative expenses for the full year ended December 31, 2017, excluding restructuring costs, were $27.7 million, compared to $49.2 millionfor the same period in 2016. This year-over-year $21.5 milliondecrease was primarily driven by decreased headcount and employee related costs, reduced consulting and marketing, and reduced travel, facilities and other expenses. These quarterly and annual decreases resulted from the implementation of OvaScience’s refined corporate strategy in fiscal 2017.
Net loss for the quarter ended
December 31, 2017was $8.5 million, or $0.24per share, compared to a net loss of $22.6 million, or $0.64per share, for the same period in 2016. Net loss for the full year ended December 31, 2017was $51.0 millionor $1.43per share, compared to a net loss of $82.3 million, or $2.56per share, for the same period in 2016. The net loss for the quarter and year-ended December 31, 2017includes restructuring charges of $0.2 millionand $4.0 million, respectively, compared to $5.4 millionfor the same periods in 2016.
The cash outlays related to the restructurings in the fourth quarter of
This press release includes forward-looking statements about the Company’s plans for the OvaPrime treatment, OvaTure treatment and AUGMENT treatment, including statements relating to the Company’s (i) plans to conduct additional preclinical studies to further characterize egg precursor (EggPC) cells, evaluate the impact of our improved cell processing techniques, and inform the final design of the proposed Phase 1b/2a OvaPrime clinical study, (ii) plans to apply the learnings from these preclinical studies to OvaTure and AUGMENT as appropriate, (iii) plans to finalize and give an update on the OvaPrime development plan, and begin enrollment in the planned Phase 1b/2a OvaPrime clinical trial, in the second half of 2018, (iv) plans to realize the promise of treatments derived from the Company’s EggPC cell technology platform, (v) expectations relating to data readouts from the ongoing Phase 1 OvaPrime study, (vi) expectation that the termination of the Intrexon Exclusive Channel Collaboration Agreement will not adversely impact or slow the development of OvaTure, and (vii) expected restructuring-related cash outlays and the Company’s anticipated cash runway. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the science underlying our treatments (including the OvaPrime, OvaTure and AUGMENT treatments), which is unproven; our ability to obtain regulatory approval or licenses where necessary for our treatments; our ability to develop our treatments on the timelines we expect, if at all; our ability to commercialize our treatments, on the timelines we expect, if at all; risks associated with preclinical, clinical and other studies; development risk; risks associated with dependence on third parties, including our partners; operational risks; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.
|Condensed Consolidated Balance Sheets|
|Cash and cash equivalents||$||15,703||$||43,930|
|Prepaid expenses and other current assets||1,578||2,056|
|Total current assets||68,781||116,444|
|Property and equipment, net||3,113||5,572|
|Investment in joint venture||146||65|
|Other long-term assets||24||24|
|Liabilities and stockholders’ equity|
|Accrued expenses and other current liabilities||5,562||11,026|
|Total current liabilities||7,804||13,209|
|Other non-current liabilities||751||1,116|
|Total stockholders’ equity||64,298||108,217|
|Total liabilities and stockholders’ equity||$||72,853||$||122,543|
|Condensed Consolidated Statements of Operations|
|(In thousands, except per share data)|
Three Months Ended
Twelve Months Ended
|Costs and expenses:|
|Cost of revenues||218||1,433||790||5,401|
|Research and development||3,560||4,709||18,337||21,641|
|Selling, general and administrative||4,809||10,947||27,744||49,223|
|Total costs and expenses||8,775||22,489||50,901||81,665|
|Loss from operations||(8,684)||(22,368)||(50,606)||(81,012)|
|Interest income, net||(191)||(162)||(752)||(659)|
|Other income, net||(1)||82||36||164|
|Loss from equity method investment||3||371||1,018||1,542|
|Loss before income taxes||$||(8,494)||(22,658)||(50,908)||(82,059)|
|Income tax expense||34||(15)||67||201|
|Net loss per share—basic and diluted||$||(0.24)||$||(0.64)||$||(1.43)||$||(2.56)|
|Weighted average number of shares used in net loss per share—basic and diluted||35,687||35,612||35,675||32,148|
Media and Investor Contact
Jonathan Gillis, 617-420-8639